American Regent Recalls Papaverine Hydrochloride Injection Due to Glass Particulate Contamination Risks

Summary

American Regent, Inc. has issued a voluntary nationwide recall for a lot of Papaverine Hydrochloride Injection (60 mg/2 mL) following discovery of glass particles. This recall impacts clinicians using the vasodilator for off-label reproductive health applications and requires immediate inventory isolation to prevent systemic embolism.

The launch adds another node to the Care Delivery lane of the map. Distribution footprint, pricing, and access channels are the operator-relevant read.

Sources

• OVUM Primary source